This article states part of the reporting system will include information on the willingness of a doctor to use genetic testing, well first of all we need to help the doctors to bring this full circle with the integration into the clinical side of this, as I have spoken to many MDs and they are aware...
Posted to
The Medical Quack .... by Barbara Duck
on 10-06-2008
Filed under: Medically Related, Pharma/FDA News, Genomics, drugs, Education, FDA, Pharmaceuticals, Pharmacogenomics, DNA Testing
It should be the discretion of individual physicians, not insurance companies or pharmacies, to substitute a branded biologic for a biosimilar, which goes back to putting the physician in the decision making process, not the non clinical analyzers. While the search for "cheap" continues...
Posted to
The Medical Quack .... by Barbara Duck
on 08-14-2008
Filed under: Medically Related, Technology, My Commentaries, DNA, Genomics, Biotech, Research, Congress, Pharmaceuticals, Biosimilars
Part of the success of Amgen was using a smaller amount of individuals for clinical trials, and looking at results during the trial instead of an overall evaluation process at the conclusion. It also helps keep the cost of the clinical trials down by conducting studies for biomarkers, or signature...
Warfarin is the second-most-likely drug, to cause adverse events requiring hospitalization. The use of warfarin sensitivity testing in the U.S. could avoid 85,000 serious-bleeding incidents. More in the way of personalized medicine and if you were a patient determined to have an adverse reaction...